Introduction
Kava (Piper methysticum) is a plant native to the South Pacific islands, where it has been used for centuries in traditional medicine and cultural practices. The roots of the kava plant are typically ground into a powder and mixed with water to create a beverage consumed for its relaxing and anxiety-reducing effects (Sarris et al., 2013; Smith & Leiras, 2018). In recent years, kava has gained popularity worldwide as a natural remedy for anxiety, stress, and sleep disorders.
This article aims to provide a comprehensive overview of the benefits of kava, focusing on its anxiolytic and sleep-promoting properties. We will explore the scientific evidence supporting these effects, discuss the potential mechanisms of action, and address safety concerns related to kava use. By the end of this article, readers will have a better understanding of the potential benefits and risks associated with kava consumption, enabling them to make informed decisions about incorporating this herbal remedy into their wellness routines.
Anxiolytic Effects of Kava
Systematic Review and Meta-Analysis
Kava has been extensively studied for its anxiolytic properties, with several randomised controlled trials investigating its efficacy in treating anxiety disorders. A systematic review and meta-analysis by Smith and Leiras (2018) analysed seven randomised controlled trials (N=380) comparing kava extract to placebo. The results indicated that kava extract was superior to placebo in reducing anxiety symptoms, with a small but significant effect size (Smith & Leiras, 2018). This finding suggests that kava may be an effective natural treatment option for individuals experiencing anxiety.
However, it is important to note that the included studies varied in their methodologies, kava preparations, and dosages, which may have influenced the overall results. Additionally, the long-term efficacy and safety of kava for anxiety treatment were not assessed in this meta-analysis, highlighting the need for further research in this area.
16-Week Double-Blind, Randomised, Placebo-Controlled Study
In a more recent 16-week, double-blind, randomised, placebo-controlled study, Sarris et al. (2020) compared the efficacy of kava to placebo in treating generalised anxiety disorder (GAD) in a larger sample size (N=171). Surprisingly, the study found no significant difference between kava and placebo in reducing anxiety symptoms, with 17.4% of kava users achieving remission compared to 23.8% in the placebo group (Sarris et al., 2020). These findings contradict earlier studies and suggest that the anxiolytic effects of kava may be less robust than previously thought.
The authors noted that the kava preparation used in this study differed from those used in previous trials, which may have contributed to the discrepant results. Additionally, the study population consisted of individuals with moderate to severe GAD, and it is possible that kava may be more effective in treating milder forms of anxiety.
6-Week Randomised Controlled Trial
An earlier 6-week randomised controlled trial by Sarris et al. (2013) investigated the effects of an aqueous kava extract (120-240 mg kavalactones daily) on anxiety symptoms in a sample of 75 participants. The study found a significant reduction in anxiety symptoms in the kava group compared to placebo, with no changes in liver enzymes observed (Sarris et al., 2013). These results support the anxiolytic properties of kava and suggest that aqueous kava preparations may be safer than ethanolic or acetonic extracts, which have been associated with rare cases of liver toxicity.
However, the sample size in this study was relatively small, and the duration of treatment was shorter compared to the 16-week trial by Sarris et al. (2020). Long-term studies with larger sample sizes are needed to confirm the efficacy and safety of aqueous kava preparations in treating anxiety disorders.
Sleep-Promoting Effects of Kava
Systematic Review
In addition to its anxiolytic properties, kava has also been investigated for its potential to improve sleep quality. However, the evidence supporting the sleep-promoting effects of kava is limited. A systematic review by Smith and Leiras (2018) found insufficient evidence to recommend kava for the treatment of sleep disorders, highlighting the need for more research in this area.
Randomised, Placebo-Controlled Trial
Despite the lack of conclusive evidence from systematic reviews, a randomised, placebo-controlled trial by Lehrl (2004) investigated the effects of kava on sleep quality in a sample of 24 participants. The study found that kava (200 mg/day) significantly improved sleep quality and reduced stress-induced insomnia compared to placebo (Lehrl, 2004). These findings suggest that kava may have potential as a natural sleep aid, particularly for individuals experiencing stress-related sleep disturbances.
However, the sample size in this study was small, and the duration of treatment was limited to four weeks. Larger, long-term trials are needed to confirm the sleep-promoting effects of kava and determine the optimal dosage and duration of use for improving sleep quality.
Mechanisms of Action
Kavalactones and GABA Receptors
The anxiolytic and sleep-promoting effects of kava are believed to be mediated by several mechanisms, primarily involving the active compounds known as kavalactones. Kavalactones are thought to interact with gamma-aminobutyric acid (GABA) receptors in the brain, potentially enhancing the activity of this inhibitory neurotransmitter (Chua et al., 2016). GABA is known to play a crucial role in regulating anxiety and promoting relaxation, and the modulation of GABA receptors by kavalactones may underlie the anxiolytic effects of kava.
In vitro studies have demonstrated that specific kavalactones, such as kavain and dihydrokavain, can potentiate GABA-induced currents in recombinant GABA(A) receptors expressed in Xenopus oocytes (Chua et al., 2016). These findings provide a potential molecular mechanism for the anxiolytic and sedative effects of kava, although further research is needed to confirm these interactions in vivo and to determine the specific contributions of individual kavalactones to the overall effects of kava.
Kavain and Neuronal Excitability
In addition to modulating GABA receptors, specific kavalactones have been shown to influence neuronal excitability through other mechanisms. For example, kavain, a major kavalactone found in kava, has been demonstrated to reduce neuronal excitability by inhibiting voltage-gated sodium channels and reducing intracellular calcium influx (Magura et al., 1997). These effects may contribute to the anxiolytic and neuroprotective properties of kava.
In rat hippocampal neurons, kavain was found to inhibit voltage-operated Na+ channels, leading to a reduction in neuronal excitability (Magura et al., 1997). This inhibition of sodium channels may help to stabilise neuronal activity and prevent excessive excitation, which has been implicated in the development of anxiety disorders. Additionally, the reduction of intracellular calcium influx by kavain may help to protect neurons from excitotoxicity and oxidative stress, further supporting the potential neuroprotective effects of kava.
Safety and Liver Toxicity Concerns
Review of Case Reports
Despite the potential benefits of kava, concerns have been raised regarding its safety, particularly in relation to liver toxicity. A review of 14 case reports of kava-related liver toxicity by Teschke et al. (2011) found that most cases involved the use of ethanolic or acetonic kava extracts, suggesting that the extraction solvent may play a role in the hepatotoxicity risk. The authors proposed that the use of traditional aqueous kava preparations may be safer than modern ethanolic or acetonic extracts, which may contain higher concentrations of potentially hepatotoxic compounds.
However, it is important to note that the case reports reviewed by Teschke et al. (2011) were limited in number and provided varying levels of detail regarding the specific kava products consumed, dosages, and duration of use. Additionally, the presence of confounding factors, such as pre-existing liver conditions or concomitant use of other medications, cannot be ruled out in these cases. As such, a direct causal relationship between kava use and liver toxicity cannot be definitively established based on these case reports alone.
Liver Enzyme Elevations in Randomised Controlled Trial
In the 16-week randomised controlled trial by Sarris et al. (2020), which compared kava to placebo for the treatment of GAD, kava users were found to have a higher incidence of liver enzyme elevations compared to the placebo group, despite the use of an aqueous extract. This finding raises concerns about the potential hepatotoxicity of kava, even when using aqueous preparations that are generally considered safer than ethanolic or acetonic extracts.
However, the authors noted that the liver enzyme elevations observed in the kava group were generally mild and transient, with no participants experiencing severe liver injury or requiring treatment discontinuation due to liver-related adverse events (Sarris et al., 2020). Additionally, the study did not include a long-term follow-up to assess the persistence or resolution of liver enzyme elevations after the cessation of kava use.
Potentially Hepatotoxic Compounds in Kava
Recent research has identified specific compounds in kava that may be responsible for its potential hepatotoxicity. Flavokavains A and B, which are minor constituents of kava, have been shown to exhibit cytotoxic effects in vitro and to potentiate acetaminophen-induced hepatotoxicity in mice (Zhou et al., 2010; Narayanapillai et al., 2014). These findings suggest that flavokavains may contribute to the hepatotoxic risk associated with kava use, particularly when combined with other hepatotoxic agents or in individuals with pre-existing liver conditions.
However, it is important to note that flavokavains are present in relatively low concentrations in traditional aqueous kava preparations, which may explain the lower incidence of liver toxicity associated with these preparations compared to modern ethanolic or acetonic extracts (Zhou et al., 2010). Additionally, the hepatotoxic effects of flavokavains have primarily been demonstrated in vitro and in animal models, and their relevance to human kava consumption remains to be fully elucidated.
To minimise the potential risk of liver toxicity associated with kava use, it is recommended that individuals consume traditional aqueous kava preparations rather than ethanolic or acetonic extracts, and to avoid combining kava with other hepatotoxic agents or medications. Individuals with pre-existing liver conditions or a history of liver disease should exercise caution when considering kava use and consult with a healthcare provider before consuming kava products.
Optimal Dosage and Duration of Use
The optimal dosage and duration of use for kava in the treatment of anxiety and sleep disorders remain to be fully established, as studies have employed varying kava preparations, dosages, and treatment durations. In the 6-week randomised controlled trial by Sarris et al. (2013), which found a significant reduction in anxiety symptoms with kava use, participants consumed an aqueous extract containing 120-240 mg of kavalactones daily. This dosage range appears to be well-tolerated and effective in the short-term treatment of anxiety, although the long-term safety and efficacy of this dosage remain to be determined.
In the 16-week randomised controlled trial by Sarris et al. (2020), which found no significant difference between kava and placebo in reducing anxiety symptoms, participants consumed a standardised aqueous extract containing 240 mg of kavalactones daily. The discrepancy in findings between this study and the 6-week trial by Sarris et al. (2013) suggests that the optimal dosage and duration of kava use for anxiety treatment may vary depending on the specific kava preparation and the severity of anxiety symptoms.
For sleep-related benefits, the randomised controlled trial by Lehrl (2004) found that a daily dose of 200 mg of kava significantly improved sleep quality and reduced stress-induced insomnia over a 4-week period. However, the long-term efficacy and safety of this dosage for sleep promotion remain to be established.
Given the variability in kava preparations, dosages, and treatment durations used in clinical trials, as well as the potential risk of liver toxicity associated with certain kava extracts, it is recommended that individuals consult with a healthcare provider before consuming kava products. A qualified healthcare professional can help to determine the most appropriate kava preparation, dosage, and duration of use based on an individual’s specific needs, medical history, and potential drug interactions.
Additionally, individuals should be advised to start with the lowest effective dose of kava and to monitor for any adverse effects, particularly those related to liver function. Regular liver function tests may be warranted for individuals consuming kava products, especially those using ethanolic or acetonic extracts or consuming high doses of kava for extended periods.
Interactions with Medications and Contraindications
Kava has the potential to interact with several medications, particularly those that are metabolised by the cytochrome P450 (CYP) enzyme system in the liver. Kavalactones have been shown to inhibit various CYP enzymes, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (Mathews et al., 2005). As a result, kava may increase the plasma concentrations and potential toxicity of medications that are substrates for these enzymes, such as certain antidepressants, antipsychotics, and anticonvulsants.
For example, kava has been reported to increase the sedative effects of benzodiazepines, such as alprazolam and diazepam, which are commonly prescribed for anxiety disorders (Izzo & Ernst, 2009). The concomitant use of kava and benzodiazepines may lead to excessive sedation and impairment of cognitive and motor functions, particularly in elderly individuals or those with pre-existing cognitive impairment.
Kava may also interact with alcohol, leading to increased sedation and potential liver toxicity (Teschke et al., 2011). The combination of kava and alcohol has been associated with several cases of severe liver injury, and individuals should be advised to avoid consuming alcohol while using kava products.
In addition to drug interactions, kava use is contraindicated in certain populations. Pregnant and breastfeeding women should avoid consuming kava due to the lack of safety data and the potential for kavalactones to cross the placental barrier and enter breast milk (Sarris et al., 2011). Individuals with pre-existing liver conditions, such as hepatitis or cirrhosis, should also avoid kava use due to the potential risk of exacerbating liver damage.
Kava use may also be contraindicated in individuals with Parkinson’s disease or those taking dopaminergic medications, as kavalactones have been shown to interfere with dopamine metabolism and may worsen parkinsonian symptoms (Izzo & Ernst, 2009). Additionally, individuals with a history of depression or bipolar disorder should use kava with caution, as the sedative effects of kava may exacerbate depressive symptoms or trigger manic episodes in susceptible individuals.
To minimise the risk of drug interactions and adverse effects, individuals should be advised to disclose their use of kava and other herbal supplements to their healthcare providers, particularly when starting new medications or undergoing medical procedures. Healthcare professionals should also be aware of the potential interactions and contraindications associated with kava use and should monitor patients consuming kava products for any signs of adverse effects or worsening of pre-existing conditions.
Future Research Directions
While the current body of evidence suggests that kava may be a promising natural treatment for anxiety and sleep disorders, several areas of research require further investigation to fully elucidate the therapeutic potential and safety profile of this herbal medicine.
One key area of future research is the identification of the specific kavalactones or combinations of kavalactones that are responsible for the anxiolytic and sleep-promoting effects of kava. While several kavalactones, such as kavain and dihydrokavain, have been shown to modulate GABA receptors and reduce neuronal excitability, the relative contributions of these compounds to the overall effects of kava remain unclear (Chua et al., 2016; Magura et al., 1997). By isolating and characterising the effects of individual kavalactones, researchers may be able to develop standardised kava preparations with optimised therapeutic profiles and reduced risk of adverse effects.
Another important area of research is the investigation of the long-term efficacy and safety of kava use for anxiety and sleep disorders. While several randomised controlled trials have demonstrated the short-term benefits of kava for these conditions (Sarris et al., 2013; Lehrl, 2004), the long-term effects of kava use remain largely unknown. Future studies should employ longer treatment durations and follow-up periods to assess the persistence of therapeutic effects and the potential for adverse events, such as liver toxicity, to develop over time.
The potential for kava to interact with medications and other herbal supplements also requires further investigation. While some studies have identified potential interactions between kava and certain medications, such as benzodiazepines and antidepressants (Izzo & Ernst, 2009), the full spectrum of drug interactions associated with kava use remains to be elucidated. Future research should systematically evaluate the effects of kava on the pharmacokinetics and pharmacodynamics of commonly prescribed medications, as well as the safety and efficacy of kava when used in combination with other herbal supplements.
Finally, future research should aim to identify the optimal dosage and duration of kava use for specific indications, such as anxiety and sleep disorders. While some studies have suggested that daily doses of 120-240 mg of kavalactones may be effective for anxiety treatment (Sarris et al., 2013), and 200 mg of kava may improve sleep quality (Lehrl, 2004), the optimal dosage and duration of use may vary depending on the specific kava preparation and the severity of symptoms. By conducting dose-response studies and comparing the effects of different kava preparations, researchers can provide more precise guidance on the use of kava for specific therapeutic applications.
In conclusion, while the current evidence supports the potential of kava as a natural treatment for anxiety and sleep disorders, further research is needed to fully understand its therapeutic potential, safety profile, and optimal use. By addressing these key areas of investigation, future studies can help to inform the development of safe and effective kava-based therapies for the management of these common mental health conditions.
Conclusion
Kava (Piper methysticum) has demonstrated promising anxiolytic and sleep-promoting effects in several randomised controlled trials, suggesting its potential as a natural treatment option for anxiety and sleep disorders. The anxiolytic properties of kava have been supported by a systematic review and meta-analysis, which found a small but significant effect size in favour of kava compared to placebo (Smith & Leiras, 2018). However, the efficacy of kava for anxiety remains inconsistent across studies, with a recent 16-week trial finding no significant difference between kava and placebo in reducing anxiety symptoms (Sarris et al., 2020).
The sleep-promoting effects of kava have been less extensively studied, with limited evidence supporting its use for the treatment of sleep disorders. While a randomised controlled trial found that kava significantly improved sleep quality and reduced stress-induced insomnia (Lehrl, 2004), a systematic review concluded that there was insufficient evidence to recommend kava for the treatment of sleep disorders (Smith & Leiras, 2018).
The potential mechanisms underlying the anxiolytic and sleep-promoting effects of kava include the modulation of GABA receptors by kavalactones (Chua et al., 2016) and the reduction of neuronal excitability by specific compounds, such as kavain (Magura et al., 1997). However, rare cases of liver toxicity associated with kava use have raised concerns about its safety, particularly with ethanolic or acetonic extracts (Teschke et al., 2011). The identification of potentially hepatotoxic compounds, such as flavokavains A and B (Zhou et al., 2010; Narayanapillai et al., 2014), highlights the need for further research to establish the safety profile of kava and to develop standardised preparations that minimise the risk of adverse effects.
In conclusion, while kava shows promise as a natural treatment for anxiety and sleep disorders, more research is needed to establish its efficacy, safety, and optimal dosage and duration of use. Future studies should aim to identify the specific kavalactones responsible for the therapeutic effects of kava, investigate its long-term efficacy and safety, and evaluate its potential interactions with medications and other herbal supplements. Individuals considering kava for the management of anxiety or sleep disorders should consult with a healthcare provider to weigh the potential benefits and risks and to determine the most appropriate use of this herbal medicine based on their individual circumstances.
Key Highlights
- Kava is a plant native to the South Pacific islands that has been used traditionally as a ceremonial drink and herbal medicine for centuries
- Kava contains active compounds called kavalactones that have anxiolytic, analgesic, and anti-inflammatory effects
- Kava has shown promise in clinical trials for treating anxiety disorders with a good safety profile at normal doses
- Kava also has potential anti-cancer and chemopreventive properties based on preclinical research
- The composition and effects of kava products can vary widely based on the cultivar, plant parts used, extraction method, and dosage
Actionable Tips
- Look for noble kava cultivars and aqueous root extracts, which are used traditionally and appear to have the best efficacy and safety
- Avoid kava products made from aerial plant parts or extracted with organic solvents, which can have higher levels of potentially toxic compounds
- Follow dosage recommendations and do not exceed 250 mg kavalactones per day for chronic use
- Be cautious about potential drug interactions and do not use kava with substances that are hard on the liver like alcohol or acetaminophen
- Consult your doctor before using kava, especially if you have liver problems or are taking medications
Here are five relevant FAQ questions and answers for readers of this article:
What are the potential side effects of kava and how can they be minimized?
Common side effects of kava include headache, dizziness, drowsiness, and skin rash. Rare but serious side effects like liver toxicity have occurred, mainly with misuse of poor quality products. To minimize risks, use noble kava cultivars at recommended doses, avoid extracts made with organic solvents, and do not use kava if you have liver disease or drink alcohol heavily. Discontinue use if you develop symptoms like yellowing of the eyes or skin, abdominal pain, or dark urine.
How does kava compare to prescription anti-anxiety medications?
Kava appears to be as effective as some anti-anxiety drugs like benzodiazepines for treating generalized anxiety disorder, with a lower risk of dependency or withdrawal. However, kava does not work as quickly as drugs and may require several weeks of use for full benefits. Kava is also not appropriate for severe anxiety or panic attacks. Consult your doctor to determine the best approach for your individual needs.
Can kava be used long-term or is it only for short-term situational anxiety?
Noble kava cultivars appear to be safe and effective for long-term daily use based on their traditional use in the South Pacific. Clinical trials have shown benefits for chronic anxiety disorders with up to 6 months of use. However, long-term safety data is limited, especially for non-noble cultivars and solvent extracts. Consult your doctor if using kava continuously for longer than 3 months.
Is it safe to use kava while pregnant or breastfeeding?
There is not enough research on the safety of kava during pregnancy and lactation. While traditional use in the South Pacific does not prohibit kava for pregnant or breastfeeding women, it is best to err on the side of caution and avoid kava until more is known. The active compounds in kava can pass into breast milk and the effects on a developing baby are unknown. Consult your OB/GYN for guidance.
Can kava be used to help with insomnia and sleep disturbances?
Kava has mild sedative effects that may help with sleep onset due to its anxiolytic properties. One clinical trial found kava extract to be effective for stress-induced insomnia. However, kava does not appear to increase deep sleep or have major effects on sleep architecture. It is likely most helpful for anxiety-related insomnia as opposed to other sleep disorders. Talk to your doctor if you have chronic insomnia, as other treatments may be more appropriate.
References
Chua, H. C., Christensen, E. T., Hoestgaard-Jensen, K., Hartiadi, L. Y., Ramzan, I., Jensen, A. A., … & Chebib, M. (2016). Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors: Functional characteristics and molecular mechanism. PLoS One, 11(6), e0157700. https://doi.org/10.1371/journal.pone.0157700
Lehrl, S. (2004). Clinical efficacy of kava extract WS® 1490 in sleep disturbances associated with anxiety disorders: Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. Journal of Affective Disorders, 78(2), 101-110. https://doi.org/10.1016/S0165-0327(02)00238-0
Magura, E. I., Kopanitsa, M. V., Gleitz, J., Peters, T., & Krishtal, O. A. (1997). Kava extract ingredients,(±)-methysticin and (±)-kavain inhibit voltage-operated Na+-channels in rat CA1 hippocampal neurons. Neuroscience, 81(2), 345-351. https://doi.org/10.1016/S0306-4522(97)00177-2
Narayanapillai, S. C., Leitzman, P., O’Sullivan, M. G., & Xing, C. (2014). Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. Chemical Research in Toxicology, 27(10), 1871-1876. https://doi.org/10.1021/tx5003194
Sarris, J., Stough, C., Bousman, C. A., Wahid, Z. T., Murray, G., Teschke, R., … & Schweitzer, I. (2013). Kava in the treatment of generalized anxiety disorder: A double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology, 33(5), 643-648. https://doi.org/10.1097/JCP.0b013e318291be67
Sarris, J., Byrne, G. J., Bousman, C. A., Cribb, L., Savage, K. M., Holmes, O., … & Ee, C. (2020). Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Australian & New Zealand Journal of Psychiatry, 54(3), 288-297. https://doi.org/10.1177/0004867419891246
Smith, K., & Leiras, C. (2018). The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials. Complementary Therapies in Clinical Practice, 33, 107-117. https://doi.org/10.1016/j.ctcp.2018.09.003
Teschke, R., Sarris, J., & Lebot, V. (2011). Kava hepatotoxicity solution: A six-point plan for new kava standardization. Phytomedicine, 18(2-3), 96-103. https://doi.org/10.1016/j.phymed.2010.10.002
Zhou, P., Gross, S., Liu, J. H., Yu, B. Y., Feng, L. L., Nolta, J., … & Qiu, S. X. (2010). Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-κB and MAPK signaling pathways. The FASEB Journal, 24(12), 4722-4732. https://doi.org/10.1096/fj.10-163311
